EFPIA
13.5.2022 06:02:05 CEST | Business Wire | Press release
More than two years after the COVID-19 pandemic started, healthcare systems are taking stock of the lessons learnt to strengthen their response and improve the health outcomes of patients across disease areas. In this context, the European Federation of Pharmaceutical Industries and Associations (EFPIA) CVD Network commissioned a report in collaboration with PwC on “Boosting cardiovascular health in Europe: towards more resilient and equitable healthcare” , to assess the impact of COVID-19 on cardiovascular (CVD) care and to explore possible policy actions to strengthen the healthcare systems’ response to CVDs.
The report finds that:
- Cardiovascular disease (CVD) is the major cause of mortality and morbidity across Europe, affecting almost 95 million patients and, notably causing 1.24 million acute coronary events each year.
- CVD accounts for almost one-third of all premature deaths and is responsible for 23 % of all disability-adjusted life years (DALYs) measured across Europe, exceeding the burden caused by all other non-communicable diseases (NCDs), including cancer.
- At the same time, many CVDs are preventable or, at least, manageable with appropriate interventions, often more so than other major NCDs. Overall, about 70% of the CVD burden is attributable to risk factors that can be controlled or modified, such as hypertension, high cholesterol or diabetes.
- COVID-19 has made things worse. The pandemic has increased the risk of hospitalisation and death for people with CVD and put healthcare systems under strain, disrupting detection and care pathways and exposing existing disparities in CVD care.
- Short-term shocks, similar to the pandemic, are likely to become more frequent, thus boosting healthcare demand, and stretching healthcare services even further.
- Evolving disease patterns will force healthcare systems to reshape their care delivery models. With 130 million Europeans expected to be over the age of 65 by 2050, CVD-related healthcare demand is bound to grow and transform over the coming decades.
Following the findings, the report offers a series of concrete policy recommendations that aim to re-design CVD care and equip European healthcare systems with the necessary tools to cope with future crises:
-
Strengthen population screening
- Broaden screening programmes for genetic and metabolic risk factors
- Simplify access to screening, especially for vulnerable populations
-
Ensure treatment initiation, maintenance, and follow-up for at-risk patients
- Re-design healthcare systems to reward outcomes
- Strengthen digital health and information sharing to improve disease management
-
Foster data-driven decision making
- Harness the potential of data-driven solutions to inform CVD policies and support clinical decision-making and value-based care delivery
“Cardiovascular diseases are Europe’s biggest health challenge. The time to act is now. Building on the available evidence, we need bold policy action for better population health in Europe ” commented Christian Thonke and Sean Lybrand, co-Chairs of the EFPIA CVD Network.
The Report calls on all CVD stakeholders to play their part in advancing CVD prevention, detection and care, by putting the spotlight on secondary prevention and encouraging a smarter use of digital technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005572/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 202626.5.2026 17:00:00 CEST | Press release
Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies. Real-world data from the MILOS study across multiple European cohorts demonstrate consistent effectiveness and safety profile in routine clinical practice.1,2,3,4 Analysis from the CLEAR Outcomes trial underscores the impact of bempedoic acid on cardiovascular risks, including stroke and venous thromboembolism (VTE).5,6 Daiichi Sankyo Europe’s commitment to "care for every heartbeat" is centred on providing accessible oral treatment options to ensure every patient is given a chance to reach their LDL-C goals. Daiichi Sankyo Europe (DSE) is pleased to announce its extensive scientific presence at the European Atherosclerosis Society (EAS) Congress 2026. The presentation of 15 abstracts, comprising both clinical trial analyses and real-world evidence, underscores the company's sustained investment
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
